Site Content

 December 14, 2021 Honored to announce a National Science Foundation (NSF) award to  further develop and commercialize our AIDE-360 platform that aims at facilitating the  rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false

 December 14, 2021 Honored to announce a National Science Foundation (NSF) award to  further develop and commercialize our AIDE-360 platform that aims at facilitating the  rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false

 November 17, 2021. Akttyva  Therapeutics won an IBM  prize for its AI drug-discovery program AIDE-360, which was used to discover the hits for the vascular leak program

 October 1, 2021. Akttyva  Therapeutics is a finalist of the highly selective 2021 MassChallenge  competition! We are honored to be one of only 45 companies out of 229  selected for the final round (out of over 3,000 original applications).  The winners of the final round will compete for $1M non-dilutive cash  prizes competition

https://readymag.com/MassChallenge/Finalists21/finalists/

April 1, 2021 Akttyva has established laboratories in Mansfield Bioincubator

January 10, 2021 Dr. Mario DiPaola, an experienced scientist and successful entrepreneur, joins Akttyva as Head of Research.